Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-05 20:20 • The Motley Fool Mixed Axe Cap view: Selective

Eli Lilly, the only healthcare stock in the trillion-dollar club, has rallied 400% over five years driven by its successful GLP-1 drugs Mounjaro and Zepbound. However, with a valuation of 40x trailing earnings and slowing growth prospects, the stock faces significant headwinds from intensifying competition in the GLP-1 market from companies like Pfizer and Viking Therapeutics. The author suggests the stock may have more downside risk than upside potential at current valuations.

Axe note: Eli Lilly’s rapid rise on GLP-1 drugs faces growing risks amid stiff competition and lofty valuations.

2026-10-05 20:19 • The Motley Fool Positive Axe Cap view: Selective

AMD and Intel are competing for dominance in the AI chip market. AMD is experiencing rapid growth with 34.3% revenue increase and strong data center performance, while Intel is undergoing a turnaround with improving results but negative free cash flow. The article recommends AMD as the better buy due to faster growth, cleaner business trajectory, and lower execution risk.

Axe note: AMD's rapid growth and cleaner finances make it more appealing than Intel in the AI chip race, with implications for USD/ZAR and wider tech exposure.

2026-10-05 19:30 • The Motley Fool Positive Axe Cap view: Selective

The author argues that long-term investors should view stock market crashes as buying opportunities rather than reasons to panic. He emphasizes that the S&P 500 has historically delivered ~10% average annual returns over 98 years and ~15.3% over the past 10 years, making continued investment during downturns a sound strategy for those with multi-year investment horizons.

Axe note: Crashes can offer rare entry points for investors in JSE stocks and the rand.